Survival in multiple myeloma has improved significantly over the past two decades, driven by continued innovation in treatment. As the leading hematology company, Johnson & Johnson has played a central role in this progress, with approximately 80% of patients receiving at least one of our therapies during their multiple myeloma journey.1 Today, we are advancing new treatment approaches and reimagining how multiple myeloma is treated to better support patients throughout their care journey. We are moving beyond “treat to progression” towards “treat to cure”.
More than 180,000 new cases of multiple myeloma are diagnosed globally each year
Our portfolio includes a range of therapies designed to treat multiple myeloma for every patient at every stage of the disease. This includes newer approaches, such as bispecific antibodies and CAR-T therapies, alongside foundational treatments used across the care continuum. By advancing our robust portfolio and pipeline, we are exploring additional treatment options to support patient care.
We have helped shape the standard of care for newly diagnosed patients, supported by clinical and real-world evidence. Yet multiple myeloma remains complex, and many patients will need additional therapy over time. Supporting patients throughout their disease journey with treatments used at different stages allows for more options and more personalized care.
Multiple myeloma: by the numbers
- Second most common blood cancer worldwide2
- Survival has extended from ~5 years to 15 years or more3
- Patients often require multiple lines of therapy over time4
Footnotes:
1 Johnson & Johnson. Q4 2025 Earnings Call Transcript. January 21, 2026. Available at: https://s203.q4cdn.com/636242992/files/doc_financials/2025/q4/JNJ-USQ_Transcript_2026-01-21.pdf. Accessed June 2026.
2 International Myeloma Foundation. “What Is Multiple Myeloma?” Myeloma.org. Available at: https://www.myeloma.org/what-is-multiple-myeloma. Accessed June 2026.
3 International Myeloma Foundation. “October–November 2025: What’s New in Myeloma.” Myeloma.org. Available at: https://www.myeloma.org/blog/october-november-2025-whats-new-myeloma. Accessed June 2026.
4 National Library of Medicine. PMC Article (PMC12150631). Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12150631/. Accessed June 2026.
